Basic HTML Version
THINGS ARE ABOUT
TO CHANGE IN
ANTICOAGULATION
THERAPY
Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg.
Tel: +27 (011) 348 2400 • Fax: +27 (011) 787 3766 • Company Reg. No. 1966/008618/07.
BI Ref No. 254/2010 (Nov 10)
EVERY DAY IN
SOUTH AFRICA
44
**
PATIENTS WILL HAVE AN
AF
*
RELATED STROKE
1, 2, 3
22
**
OF THEM WILL DIE
WITHIN A YEAR (50 %)
4
90 %
OF STROKE PATIENTS
WITH KNOWN AF WERE
NOT THERAPEUTICALLY
ANTICOAGULATED
4
*AF – Atrial Fibrillation
** Best Estimate
REFERENCES:
1. Stats South-Africa. Stats-Online. P0302 - Mid-year population
estimates. Updated 20 July 2010. Available from:
http://www.statssa.gov.za/publications/P0302/P03022010.pdf
2. Connor M. Stroke Management in South Africa – Who is responsible?
S Afr Psychiatry Rev 2005; 8: 125-126.
3. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to
incidence and outcome of ischemic stroke: results from a population-
based study. Stroke 2005; 36:1115-9.
4. Gladstone DJ, Bui E,Fang J, et al. Potentially Preventable Strokes in
High-Risk Patients With Atrial Fibrillation Who Are Not Adequately
Anticoagulated. Stroke 2009;40;235-240.